Common Angiotensin Receptor Blockers May Directly Modulate the Immune System Via VDR, PPAR and CCR2b

Overview

Journal Theor Biol Med Model

Publisher Biomed Central

Date 2006 Jan 13

PMID 16403216

Citations 26

Authors

Trevor G Marshall

Robert E Lee

Frances E Marshall

Affiliations

Soon will be listed here.

Abstract

Background: There have been indications that common Angiotensin Receptor Blockers (ARBs) may be exerting anti-inflammatory actions by directly modulating the immune system. We decided to use molecular modelling to rapidly assess which of the potential targets might justify the expense of detailed laboratory validation. We first studied the VDR nuclear receptor, which is activated by the secosteroid hormone 1,25-dihydroxyvitamin-D. This receptor mediates the expression of regulators as ubiquitous as GnRH (Gonadatrophin hormone releasing hormone) and the Parathyroid Hormone (PTH). Additionally we examined Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma), which affects the function of phagocytic cells, and the C-CChemokine Receptor, type 2b, (CCR2b), which recruits monocytes to the site of inflammatory immune challenge.

Results: Telmisartan was predicted to strongly antagonize (Ki asymptotically equal to 0.04 nmol) the VDR. The ARBs Olmesartan, Irbesartan and Valsartan (Ki asymptotically equal to10 nmol) are likely to be useful VDR antagonists at typical in-vivo concentrations. Candesartan (Ki asymptotically equal to 30 nmol) and Losartan (Ki asymptotically equal to 70 nmol) may also usefully inhibit the VDR. Telmisartan is a strong modulator of PPARgamma (Ki asymptotically equal to 0.3 nmol), while Losartan (Ki asymptotically equal to 3 nmol), Irbesartan (Ki asymptotically equal to 6 nmol), Olmesartan and Valsartan (Ki asymptotically equal to 12 nmol) also seem likely to have significant PPAR modulatory activity. Olmesartan and Irbesartan (Ki asymptotically equal to 9 nmol) additionally act as antagonists of a theoretical model of CCR2b. Initial validation of this CCR2b model was performed, and a proposed model for the Angiotensin II Type1 receptor (AT2R1) has been presented.

Conclusion: Molecular modeling has proven valuable to generate testable hypotheses concerning receptor/ligand binding and is an important tool in drug design. ARBs were designed to act as antagonists for AT2R1, and it was not surprising to discover their affinity for the structurally similar CCR2b. However, this study also found evidence that ARBs modulate the activation of two key nuclear receptors-VDR and PPARgamma. If our simulations are confirmed by experiment, it is possible that ARBs may become useful as potent anti-inflammatory agents, in addition to their current indication as cardiovascular drugs.

Citing Articles

Nucleus pulposus cell network modelling in the intervertebral disc.

Tseranidou S, Segarra-Queralt M, Chemorion F, Le Maitre C, Pinero J, Noailly J NPJ Syst Biol Appl. 2025; 11(1):13.

PMID: 39890859 PMC: 11785752. DOI: 10.1038/s41540-024-00479-6.

Immunomodulation and immunopharmacology in heart failure.

Markousis-Mavrogenis G, Baumhove L, Al-Mubarak A, Aboumsallem J, Bomer N, Voors A Nat Rev Cardiol. 2023; 21(2):119-149.

PMID: 37709934 DOI: 10.1038/s41569-023-00919-6.

Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway.

Hachiya K, Masuya M, Kuroda N, Yoneda M, Tsuboi J, Nagaharu K Sci Rep. 2021; 11(1):19943.

PMID: 34620946 PMC: 8497524. DOI: 10.1038/s41598-021-99412-8.

Infiltrating CCR2 monocytes and their progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation through the production of TIMP-1.

Kuroda N, Masuya M, Tawara I, Tsuboi J, Yoneda M, Nishikawa K Sci Rep. 2019; 9(1):8568.

PMID: 31189971 PMC: 6562037. DOI: 10.1038/s41598-019-45012-6.

Comparative Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Response to a Physical Activity Intervention in Older Adults: Results From the Lifestyle Interventions and Independence for Elders Study.

Brown J, Smith S, Strotmeyer E, Kritchevsky S, Gill T, Blair S J Gerontol A Biol Sci Med Sci. 2019; 75(5):1010-1016.

PMID: 31070702 PMC: 7164526. DOI: 10.1093/gerona/glz120.

References

Omdahl J, Morris H, May B . Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr. 2002; 22:139-66. DOI: 10.1146/annurev.nutr.22.120501.150216. View

Tanaka S, Green S, Quehenberger O . Differential expression of the isoforms for the monocyte chemoattractant protein-1 receptor, CCR2, in monocytes. Biochem Biophys Res Commun. 2002; 290(1):73-80. DOI: 10.1006/bbrc.2001.6149. View

Shi X, Liu S, Xiangyu J, Zhang Y, Huang J, Liu S . Structural analysis of human CCR2b and primate CCR2b by molecular modeling and molecular dynamics simulation. J Mol Model. 2002; 8(7):217-22. DOI: 10.1007/s00894-002-0089-6. View

Cabrero A, Laguna J, Vazquez M . Peroxisome proliferator-activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy. 2003; 1(3):243-8. DOI: 10.2174/1568010023344616. View

Lewis E, Lewis J . Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin Exp Nephrol. 2003; 7(1):1-8. DOI: 10.1007/s101570300000. View

Mann D, Deswal A . Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. N Engl J Med. 2003; 349(20):1963-5. DOI: 10.1056/NEJMe038163. View

Benson S, Pershadsingh H, Ho C, Chittiboyina A, Desai P, Pravenec M . Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 43(5):993-1002. DOI: 10.1161/01.HYP.0000123072.34629.57. View

Acevedo A, Stoynova L, Davis K, Solorzano R, Collins E . Role of residues 143 and 278 of the human nuclear Vitamin D receptor in the full-length and Delta165-215 deletion mutant. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):83-7. DOI: 10.1016/j.jsbmb.2004.03.051. View

Marshall T, Marshall F . Sarcoidosis succumbs to antibiotics--implications for autoimmune disease. Autoimmun Rev. 2004; 3(4):295-300. DOI: 10.1016/j.autrev.2003.10.001. View

10.

Schieffer B, Bunte C, Witte J, Hoeper K, Boger R, Schwedhelm E . Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004; 44(2):362-8. DOI: 10.1016/j.jacc.2004.03.065. View

11.

Wittke A, Weaver V, Mahon B, August A, Cantorna M . Vitamin D receptor-deficient mice fail to develop experimental allergic asthma. J Immunol. 2004; 173(5):3432-6. DOI: 10.4049/jimmunol.173.5.3432. View

12.

Casey P, GILMAN A . G protein involvement in receptor-effector coupling. J Biol Chem. 1988; 263(6):2577-80. View

13.

Goodsell D, Olson A . Automated docking of substrates to proteins by simulated annealing. Proteins. 1990; 8(3):195-202. DOI: 10.1002/prot.340080302. View

14.

Potashnik G, Lunenfeld E, Levitas E, Itskovitz J, Albutiano S, Yankowitz N . The relationship between endogenous oestradiol and vitamin D3 metabolites in serum and follicular fluid during ovarian stimulation for in-vitro fertilization and embryo transfer. Hum Reprod. 1992; 7(10):1357-60. DOI: 10.1093/oxfordjournals.humrep.a137573. View

15.

Sali A, Blundell T . Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993; 234(3):779-815. DOI: 10.1006/jmbi.1993.1626. View

16.

McDonald I, Thornton J . Satisfying hydrogen bonding potential in proteins. J Mol Biol. 1994; 238(5):777-93. DOI: 10.1006/jmbi.1994.1334. View

17.

Strader C, Fong T, Graziano M, Tota M . The family of G-protein-coupled receptors. FASEB J. 1995; 9(9):745-54. View

18.

Wallace A, Laskowski R, Thornton J . LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995; 8(2):127-34. DOI: 10.1093/protein/8.2.127. View

19.

Raz E, Tighe H, Sato Y, Corr M, Dudler J, Roman M . Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A. 1996; 93(10):5141-5. PMC: 39421. DOI: 10.1073/pnas.93.10.5141. View

20.

Morris G, Goodsell D, Huey R, Olson A . Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des. 1996; 10(4):293-304. DOI: 10.1007/BF00124499. View